Translational potential of human embryonic and induced pluripotent stem cells for myocardial repair: Insights from experimental models

Summary

Heart diseases have been a major cause of death worldwide, including developed countries. Indeed, loss of non-regenerative, terminally differentiated cardiomyocytes (CMs) due to aging or diseases is irreversible. Current therapeutic regimes are palliative in nature, and in the case of end-stage heart failure, transplantation remains the last resort. However, this option is significantly hampered by a severe shortage of donor cells and organs. Human embryonic stem cells (hESCs) can self-renew while maintaining their pluripotency to differentiate into all cell types. More recently, direct reprogramming of adult somatic cells to become pluripotent hES-like cells (a.k.a. induced pluripotent stem cells or iPSCs) has been achieved. The availability of hESCs and iPSCs, and their successful differentiation into genuine human heart cells have enabled researchers to gain novel insights into the early development of the human heart as well as to pursue the revolutionary paradigm of heart regeneration. Here we review our current knowledge of hESC-/iPSC-derived CMs in the context of two fundamental operating principles of CMs (i.e. electrophysiology and Ca²⁺-handling), the resultant limitations and potential solutions in relation to their translation into clinical (bioartificial pacemaker, myocardial repair) and other applications (e.g. as models for human heart disease and cardiotoxicity screening).

Keywords

Human embryonic stem cells - cardiomyocytes - induced pluripotent stem cells

• References

• 1 Abraham MR. et al. Antiarrhythmic engineering of skeletal myoblasts for cardiac transplantation. Circulation Res 2005; 97: 159-167.
• 2 Tse HF. et al. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 2003; 361: 47-49.
• 3 Murry CE. et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004; 428: 664-668.
• 4 Thomson JA. et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-1147.
• 5 He JQ. et al. Human embryonic stem cells develop into multiple types of cardiac myocytes: Action potential characterization. Circulation Res 2003; 93: 32-39.
• 6 Mummery C. et al. Differentiation of human embryonic stem cells to cardiomyocytes: Role of coculture with visceral endoderm-like cells. Circulation 2003; 107: 2733-2740.
• 7 Xu C. et al. Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circulation Res 2002; 91: 501-508.
• 8 Xue T. et al. Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: Insights into the development of cell-based pacemakers. Circulation 2005; 111: 11-20.
• 9 Kehat I. et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 2001; 108: 407-414.
• 10 Laflamme MA. et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007; 25: 1015-1024.
• 11 Caspi O. et al. Transplantation of human embryonic stem cell-derived cardio-myocytes improves myocardial performance in infarcted rat hearts. J Am Coll Cardiol 2007; 50: 1884-1893.
• 12 Byrne JA. et al. Producing primate embryonic stem cells by somatic cell nuclear transfer. Nature 2007; 450: 497-502.
• 13 Yang X. et al. Nuclear reprogramming of cloned embryos and its implications for therapeutic cloning. Nat Genet 2007; 39: 295-302.
• 14 Kishigami S. et al. Production of cloned mice by somatic cell nuclear transfer. Nat Protoc 2006; 01: 125-138.
• 15 Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
• 16 Meissner A. et al. Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells. Nat Biotechnol 2007; 25: 1177-1181.
• 17 Takahashi K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
• 18 Yu J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-19.
• 19 Yang L. et al. Human cardiovascular progenitor cells develop from a kdr+ embryonic-stem-cell-derived population. Nature 2008; 453: 524-528.
• 20 Bu L. et al. Human isl1 heart progenitors generate diverse multipotent cardiovascular cell lineages. Nature 2009; 460: 113-117.
• 21 Moretti A. et al. Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. Cell 2006; 127: 1151-1165.
• 22 Zwi L. et al. Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation 2009; 120: 1513-1523.
• 23 Moore JC. et al. Distinct cardiogenic preferences of two human embryonic stem cell (hesc) lines are imprinted in their proteomes in the pluripotent state. Biochem Biophys Res Commun 2008; 372: 553-558.
• 24 Bers DM. Cardiac excitation-contraction coupling. Nature 2002; 415: 198-205.
• 25 Brette F, Orchard C. T-tubule function in mammalian cardiac myocytes. Circulation Res 2003; 92: 1182-1192.
• 26 Brette F, Orchard C. Resurgence of cardiac t-tubule research. Physiology 2007; 22: 167-173.
• 27 Song LS. et al. Calcium biology of the transverse tubules in heart. Ann NY Acad Sci 2005; 1047: 99-111.
• 28 Fu JD. et al. Crucial role of the sarcoplasmic reticulum in the developmental regulation of Ca2+ transients and contraction in cardiomyocytes derived from embryonic stem cells. Faseb J 2006; 20: 181-183.
• 29 Fu JD. et al. Developmental regulation of intracellular calcium transients during cardiomyocyte differentiation of mouse embryonic stem cells. Acta Pharmacol Sin 2006; 27: 901-910.
• 30 Dolnikov K. et al. Functional properties of human embryonic stem cell-derived cardiomyocytes: Intracellular ca2+ handling and the role of sarcoplasmic reticulum in the contraction. Stem Cells 2006; 24: 236-245.
• 31 Liu J. et al. Functional sarcoplasmic reticulum for calcium-handling of human embryonic stem cell-derived cardiomyocytes: Insights for driven maturation. Stem Cells 2007; 25: 3038-3044.
• 32 Fu JD. et al. Na+/Ca2+ exchanger is a determinant of excitation-contraction coup-ling in human embryonic stem cell-derived ventricular cardiomyocytes. Stem Cells Dev. 2009. epub ahead of print.
• 33 Lieu DK. et al. Absence of transverse tubules contributes to non-uniform Ca2+ wavefronts in mouse and human embryonic stem cell-derived cardiomyocytes. Stem Cells Dev 2009; 18: 1493-1500.
• 34 Franzini-Armstrong C. et al. Shape, size, and distribution of Ca(2+) release units and couplons in skeletal and cardiac muscles. Biophys J 1999; 77: 1528-1539.
• 35 Zhang L. et al. Complex formation between junctin, triadin, calsequestrin, and the ryanodine receptor. Proteins of the cardiac junctional sarcoplasmic reticulum membrane. J Biol Chem 1997; 272: 23389-23397.
• 36 Beard NA. et al. Calsequestrin and the calcium release channel of skeletal and cardiac muscle. Progr Biophys Mol Biol 2004; 85: 33-69.
• 37 Bassani JW. et al. Fractional SR Ca release is regulated by trigger Ca and SR Ca content in cardiac myocytes. Am J Physiol 1995; 268: C1313-C1319.
• 38 Shannon TR. et al. Potentiation of fractional sarcoplasmic reticulum calcium release by total and free intra-sarcoplasmic reticulum calcium concentration. Bio-phys J 2000; 78: 334-343.
• 39 Lukyanenko V. et al. Regulation of calcium release by calcium inside the sarcoplasmic reticulum in ventricular myocytes. Pflugers Arch 1996; 432: 1047-1054.
• 40 Gyorke I. et al. The role of calsequestrin, triadin, and junctin in conferring cardiac ryanodine receptor responsiveness to luminal calcium. Biophys J 2004; 86: 2121-2128.
• 41 Szegedi C. et al. Calsequestrin: More than 'only' a luminal ca2+ buffer inside the sarcoplasmic reticulum. Biochem J 1999; 337: 19-22.
• 42 Ohkura M. et al. Dual regulation of the skeletal muscle ryanodine receptor by triadin and calsequestrin. Biochemistry 1998; 37: 12987-12993.
• 43 Terentyev D. et al. Calsequestrin determines the functional size and stability of cardiac intracellular calcium stores: Mechanism for hereditary arrhythmia. Proc Natl Acad Sci USA 2003; 100: 11759-11764.
• 44 Azene EM. et al. Non-equilibrium behavior of hcn channels: Insights into the role of hcn channels in native and engineered pacemakers. Cardiovasc Res 2005; 67: 263-273.
• 45 Lieu DK. et al. Overexpression of hcn-encoded pacemaker current silences bioartificial pacemakers. Heart Rhythm 2008; 05: 1310-1317.
• 46 Chan YC, Siu CW, Lau YM. et al. Synergistic effects of inward rectifier (I) and pacemaker (I) currents on the induction of bioengineered cardiac automaticity.. J Cardiovasc Electrophysiol 2009; 20: 1048-1054.
• 47 Siu CW. et al. Hcn-encoded pacemaker channels: From physiology and biophysics to bioengineering. J Membr Biol 2006; 214: 115-122.
• 48 Xue T. et al. Mechanistic role of i(f) revealed by induction of ventricular automaticity by somatic gene transfer of gating-engineered pacemaker (hcn) channels. Circulation 2007; 115: 1839-1850.
• 49 Wang K. et al. Electrophysiological properties of pluripotent human and mouse embryonic stem cells. Stem Cells 2005; 23: 1526-1534.
• 50 Jiang P. et al. Electrophysiological properties of human induced pluripotent stem cells. Am J Physiol Cell Physiol 2010; 298: C486-495.
• 51 Zhang J. et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009; 104: e30-41.
• 52 Boyett MR. et al. The sinoatrial node, a heterogeneous pacemaker structure. Cardiovasc Res 2000; 47: 658-687.
• 53 Dobrzynski H. et al. New insights into pacemaker activity: Promoting understanding of sick sinus syndrome. Circulation 2007; 115: 1921-1932.
• 54 Dubin AM, Berul CI. Electrophysiological interventions for treatment of congestive heart failure in pediatrics and congenital heart disease. Expert Rev Cardiovasc Ther 2007; 05: 111-118.
• 55 Silka MJ, Bar-Cohen Y. Pacemakers and implantable cardioverter-defibrillators in pediatric patients. Heart Rhythm 2006; 03: 1360-1366.
• 56 Walsh EP, Cecchin F. Recent advances in pacemaker and implantable defibrillator therapy for young patients. Curr Opin Cardiol 2004; 19: 91-96.
• 57 Berul CI, Cecchin F. Indications and techniques of pediatric cardiac pacing. Expert Rev Cardiovasc Ther 2003; 01: 165-176.
• 58 Sliz Jr. NB, Johns JA. Cardiac pacing in infants and children. Cardiol Rev 2000; 08: 223-239.
• 59 Miake J. et al. Gene therapy: Biological pacemaker created by gene transfer. Nature 2002; 419: 132-133.
• 60 Tse HF. et al. Bioartificial sinus node constructed via in vivo gene transfer of an engineered pacemaker hcn channel reduces the dependence on electronic pacemaker in a sick-sinus syndrome model. Circulation 2006; 114: 1000-1011.
• 61 Robinson RB. et al. I(f) and the biological pacemaker. Pharmacol Res 2006; 53: 407-415.
• 62 Qu J. et al. Hcn2 overexpression in newborn and adult ventricular myocytes: Distinct effects on gating and excitability. Circ Res 2001; 89: E8-14.
• 63 Lesso H, Li RA. Helical secondary structure of the external s3-s4 linker of pacemaker (hcn) channels revealed by site-dependent perturbations of activation phenotype. J Biol Chem 2003; 278: 22290-22297.
• 64 Tsang SY. et al. Critical intra-linker interactions of hcn1-encoded pacemaker channels revealed by interchange of s3-s4 determinants. Biochem Biophys Res Commun 2004; 322: 652-658.
• 65 Tsang SY. et al. Dissecting the structural and functional roles of the s3-s4 linker of pacemaker (hyperpolarization-activated cyclic nucleotide-modulated) channels by systematic length alterations. J Biol Chem 2004; 279: 43752-43759.
• 66 Kehat I. et al. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol 2004; 22: 1282-1289.
• 67 Plotnikov AN. et al. Xenografted adult human mesenchymal stem cells provide a platform for sustained biological pacemaker function in canine heart. Circulation 2007; 116: 706-713.
• 68 Plotnikov AN. et al. Biological pacemaker implanted in canine left bundle branch provides ventricular escape rhythms that have physiologically acceptable rates. Circulation 2004; 109: 506-512.
• 69 Cho HC. et al. Creation of a biological pacemaker by cell fusion. Circulation Res 2007; 100: 1112-1115.
• 70 Alvarez-Dolado M. et al. Fusion of bone-marrow-derived cells with purkinje neurons, cardiomyocytes and hepatocytes. Nature 2003; 425: 968-973.
• 71 Gussoni E. et al. Long-term persistence of donor nuclei in a duchenne muscular dystrophy patient receiving bone marrow transplantation. J Clin Invest 2002; 110: 807-814.
• 72 Weimann JM. et al. Stable reprogrammed heterokaryons form spontaneously in purkinje neurons after bone marrow transplant. Nat Cell Biol 2003; 05: 959-966.